Clinical trials: sponsored by ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
- Trial name
- NCT04597359
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Where
- 353 sites in United States, Guam and 1 more
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Malignant Solid Neoplasm
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients.
- Trial name
- NCT06295367
- Testing
- Best Practice, Financial Navigation, Interview
- Where
- 391 sites in United States, Guam and 1 more
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Carcinoma
Mobile Health for Adherence in Breast Cancer Patients
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication…
- Trial name
- NCT06112613
- Testing
- Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring
- Where
- 506 sites in United States, Puerto Rico
- Volunteers
- 390 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Pancreatic Neoplasm
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers.
- Trial name
- NCT04239573
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 429 sites in United States, Canada and 2 more
- Volunteers
- 770 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
This clinical trial gathers information about adolescents and young adults (AYA) and patient reported outcomes data in Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) trials to…
- Trial name
- NCT05108298
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- 347 sites in United States
- Volunteers
- 500 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Glioblastoma, IDH-Wildtype
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma.
- Trial name
- GABLE (NCT06319027)
- Testing
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia.
- Trial name
- NCT03253848
- Testing
- Simplified Patient Care Strategy, Laboratory Biomarker Analysis
- Where
- 294 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood.
- Trial name
- NCT04484818
- Testing
- Darolutamide, Goserelin Acetate, Leuprolide Acetate
- Where
- 115 sites in United States
- Volunteers
- 27 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to…
- Trial name
- NCT04233866
- Testing
- Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 760 sites in United States
- Volunteers
- 176 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01898494
- Testing
- Transoral surgery, intensity-modulated radiation therapy, cisplatin
- Where
- 58 sites in United States
- Volunteers
- 519 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Asymptomatic
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts.
- Trial name
- NCT02933489
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment
- Where
- 68 sites in United States, Germany
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Ductal Breast Carcinoma In Situ
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct.
- Trial name
- NCT02352883
- Testing
- Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure
- Where
- 76 sites in United States
- Volunteers
- 368 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Hormone-sensitive Prostate Cancer
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens.
- Trial name
- CHAARTED (NCT00309985)
- Testing
- androgen-deprivation therapy, docetaxel
- Where
- 343 sites in United States
- Volunteers
- 790 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinoma In Situ, Current Smoker
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices.
- Conditions
- Carcinoma In Situ, Current Smoker, Malignant Neoplasm, Primary Neoplasm
- Trial name
- NCT03808818
- Testing
- Behavioral, Psychological or Informational Intervention, Nicotine Replacement, Quality-of-Life Assessment
- Where
- 42 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group